Table 1.
Baseline Patient Characteristics
| Characteristic | No. | % |
|---|---|---|
| Age, years | ||
| Median | 56 | |
| Range | 25-76 | |
| Sex | ||
| Female | 14 | 42 |
| Male | 19 | 58 |
| ECOG PS | ||
| 0 | 23 | 70 |
| 1 | 10 | 30 |
| No. of prior regimens | ||
| Median | 2 | |
| Range | 2-10 | |
| Time receiving first-line imatinib, months | ||
| Median | 21 | |
| Range | 1-79 | |
| Reason for imatinib failure | ||
| Progression of disease | 30 | 90 |
| Intolerance | 3 | 10 |
| Time receiving sunitinib, months | ||
| Median | 13 | |
| Range | 2-55 | |
| Primary kinase mutation* | ||
| KIT exon 11 | 19 | |
| KIT exon 9 | 3 | |
| WT for KIT and PDGFR-α† | 8 | |
| BRAF exon 15 | 1 | |
NOTE. Time receiving prior therapy may not correlate with time to RECIST progression.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; GIST, GI stromal tumor; WT, wild type.
*
Available for 30 patients; three patients had insufficient material for analysis.
†
Eight patients (WT) had GIST with no mutations in KIT exons 9, 11, 13, or 17 or PDGFR-α exons 12, 14, or 18. Two of these eight patients were also tested for KIT exons 14,15, 1,6 and 18 and found to be WT; all WT patients were then screened for mutations in BRAF exon 15.